Get the Stockscreener App
12.56
2.94%
-0.38
After Hours:
12.56
Zymeworks Inc. stock is traded at $12.56, with a volume of 335.72K.
It is down -2.94% in the last 24 hours and up +0.08% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$12.94
Open:
$12.88
24h Volume:
335.72K
Relative Volume:
0.75
Market Cap:
$873.89M
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-8.3179
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
-10.35%
1M Performance:
+0.08%
6M Performance:
-13.97%
1Y Performance:
+20.08%
1-Day Range:
$12.52
$13.03
1-Week Range:
$12.52
$14.23
52-Week Range:
$9.03
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
12.56 | 968.49M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Zymeworks Inc. Added to High Probability Setup ListScalable Portfolio Growth Suggestions Released - metal.it
Chart based exit strategy for Zymeworks Inc.Weekly Movement Forecast With Chart Signals - Newser
Analyzing net buyer seller activity in Zymeworks Inc.Conservative Investment Setup and Risk Analysis - Newser
Analyzing Zymeworks Inc. with risk reward ratio chartsFree Daily Top Performing Stock Insights - Newser
How to read the order book for Zymeworks Inc.Entry Signal Generator with Risk Metrics - Newser
Zymeworks' IND for liver cancer antibody-drug conjugate given FDA clearance - MSN
How did ZYME's Q1 2025 EPS forecast compare to past trends? - AInvest
What factors could impact ZYME's future EPS growth? - AInvest
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate - wahanariau.com
Zymeworks’ second ADC with TOPO1 inhibitor payload to enter clinic in US - BioWorld MedTech
Zymeworks’ ZW251 Receives FDA Clearance for Clinical Trials in Liver Cancer - TipRanks
FDA clears Zymeworks’ IND for liver cancer drug candidate ZW251 By Investing.com - Investing.com Nigeria
Zymeworks Inc. Advances ZW251 into Clinical Development for Hepatocellular Carcinoma Following IND Clearance from FDA - Quiver Quantitative
Zymeworks Announces FDA Clearance of Investigational New - GlobeNewswire
FDA Green Lights Revolutionary First-in-Class Liver Cancer Drug: Zymeworks Advances New Treatment - Stock Titan
Pattern recognition hints at Zymeworks Inc. upside Free Low Risk Buy Zone Opportunity Watch - metal.it
When is Zymeworks Inc. stock expected to show significant growthDiscover high-impact stocks for growth - jammulinksnews.com
What catalysts could drive Zymeworks Inc. stock higher in 2025Explosive trading growth - jammulinksnews.com
How does Zymeworks Inc. compare to its industry peersOutstanding trading profits - jammulinksnews.com
How volatile is Zymeworks Inc. stock compared to the marketExponential return rates - jammulinksnews.com
Does Zymeworks Inc. stock perform well during market downturnsCapitalize on fast-growing stocks today - jammulinksnews.com
What are analysts’ price targets for Zymeworks Inc. in the next 12 monthsFree Stock Index Interpretation - jammulinksnews.com
What is Zymeworks Inc. company’s growth strategyGame-changing returns - jammulinksnews.com
Will Zymeworks Inc. stock benefit from AI tech trendsFree Advanced Stock Screener Access - jammulinksnews.com
What analysts say about Zymeworks Inc. stockRapid wealth multiplication - Autocar Professional
Zymeworks Inc.'s (NASDAQ:ZYME) Shareholders Might Be Looking For Exit - 富途牛牛
What drives Zymeworks Inc. stock priceFree Market Dynamics Reports - Autocar Professional
Is Zymeworks Inc. a good long term investmentPowerful growth strategies - jammulinksnews.com
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Arizona State Retirement System - Defense World
Zymeworks Announces Pricing of $100.0 Million Public Offering - Finance Monthly
Zymeworks Inc. Stock Analysis and ForecastTremendous gains - jammulinksnews.com
Teacher Retirement System of Texas Cuts Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains? - MSN
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):